Market Closed - Nasdaq Stockholm 11:29:47 2024-04-26 am EDT 5-day change 1st Jan Change
1.412 SEK -2.49% Intraday chart for Kancera AB -4.98% -68.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kancera AB Signs A License Agreement with the University of Newcastle CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study CI
Kancera AB Reports Positive Top Line Results from the FRACTAL Study CI
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145 CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145 CI
Kancera Names Successor to Outgoing Chief Medical Officer MT
Kancera AB Appoints Markus Jerling as Chief Medical Officer CI
Kancera AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kancera AB Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease CI
Kancera AB Reports Dosing of First Patient in the KANDOVA Study CI
Kancera CEO Moves to Chief Scientific Officer Role; Successor Named MT
Kancera AB Appoints Thomas Olin as Executive Vice President and Chief Scientific Officer CI
Kancera AB Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023 CI
Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sweden's Kancera Seeks Regulatory Nod for Cancer Drug Candidate Study MT
Kancera AB Submits Application to Conduct First-In-Human Study of Kand145 CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kancera AB Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Kancera AB Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies CI
Kancera AB Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma CI
Chart Kancera AB
More charts
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock Market
  2. Equities
  3. KAN Stock
  4. News Kancera AB
  5. Kancera Names Successor to Outgoing Chief Medical Officer